NasdaqGS - Delayed Quote USD

QuidelOrtho Corporation (QDEL)

42.39 -0.43 (-1.00%)
At close: 4:00 PM EDT
42.39 0.00 (0.00%)
After hours: 4:20 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Joseph M. Busky CPA Chief Financial Officer 890.63k -- 1968
Mr. Robert J. Bujarski J.D. Executive VP & COO 961.26k -- 1969
Dr. Werner Kroll Ph.D. Senior Vice President of Research & Development 1.03M -- 1957
Mr. Michael S. Iskra Executive VP & Chief Commercial Officer 870.93k -- 1970
Mr. Brian J. Blaser President, CEO & Director -- -- 1965
Ms. Louise M. Brandy Chief Information Officer -- -- 1959
Ruben Argueta Director of Investor Relations -- -- --
Ms. Michelle A. Hodges J.D. Senior VP, General Counsel & Corporate Secretary 1.8M -- 1963
Mr. William J. Ferenczy Point of Care Business Unit Leader -- -- 1956
Ms. Tamara A. Ranalli Molecular Diagnostics Business Unit Leader -- -- 1973

QuidelOrtho Corporation

9975 Summers Ridge Road
San Diego, CA 92121
United States
858 552 1100 https://www.quidelortho.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
7,100

Description

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Corporate Governance

QuidelOrtho Corporation’s ISS Governance QualityScore as of May 1, 2024 is 3. The pillar scores are Audit: 3; Board: 2; Shareholder Rights: 4; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 6, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC

QuidelOrtho Corporation Earnings Date

Recent Events

May 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 14, 2024 at 12:00 AM UTC

SC 13D/A: Tender Offer/Acquisition Reports

May 9, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 8, 2024 at 9:00 PM UTC

Q1 2024 QuidelOrtho Corp Earnings Call

May 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 29, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 2, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

February 29, 2024 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

February 21, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers